Pfizer (PFE)

After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime soon?

Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.

The company is coming back into the spotlight thanks to recent developments.

Patient investors who buy the stock may be rewarded over the long term.

If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.

Salesforce powers the engine behind America’s most ambitious brands. From retail giants to global banks, its footprint is massive. Therefore, marketers eve

As investors hedge against AI-trade valuation worries, dividend payers gain favor. AT&T, ONEOK, and Pfizer offer yields from 4.3% to 6.1% with distinct capital-return strategies.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.

Pfizer's payout ratio is above 100%, but that's not the number you should probably be watching right now.

These are two stocks that pay investors a regular income.

These healthcare leaders are unlikely to suspend their dividend programs.

Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Lookin...

While both D-Wave and Rigetti's revenues have been volatile, their valuations tell a starkly different story for quantum investors.

Pfizer is facing material patent expirations over the next two years, but that will be over by 2030.

Income generation is more about finding consistency than finding an ultra-high yield.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Pfizer has been treading water for the past six months, recording a small return of 2.6% while holding steady at $27.76. The stock also fell short of the S&P...